Notice of Proposed Sale · 144
Harmony Biosciences Holdings, Inc.
HRMYNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- HARMONY BIOSCIENCES HOLDINGS, INC.
- Issuer CIK
- 0001802665
- SEC file number
- 001-39450
- Phone
- (484)-539-9800
- Person for whose account securities are to be sold
- KUMAR BUDUR
- Relationships to issuer
- Officer
- Street
- 630 W Germantown Pike, Suite 215
- City
- Plymouth Meeting
- State / country code
- PA
- Postal code
- 19462
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 28,454 | 1,202,181.50 | 58,236,393 | 09/08/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 01/24/2025 | Restricted Stock Units | Issuer | 4,495 | N | 01/24/2025 | N/A |
| Common | 11/30/2022 | Employee Stock Purchase Plan | Issuer | 1,005 | N | 11/30/2022 | Cash |
| Common | 09/08/2026 | Exercise of Stock Options | Issuer | 22,954 | N | 09/08/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| 10b5-1 Sales for KUMAR BUDUR | Common | 09/04/2026 | 5,500 | 230,911.45 |
Seller — prior-sale row 1, entry 1
- Name
- 10b5-1 Sales for KUMAR BUDUR
- Street
- 630 W Germantown Pike, Suite 215
- City
- Plymouth Meeting
- State / country code
- PA
- Postal code
- 19462
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were acquired upon the vesting of restricted stock units during the period of 01/24/2025 through 01/25/2026. The securities to be sold were acquired under the employee stock purchase plan on 11/30/2022 and 05/31/2023.
Notice signature
- Notice date
- 09/08/2026
- Signed
- /s/ Kumar Budur
- Plan adoption dates
- 06/05/2026
Company context
Harmony Biosciences is developing and commercializing innovative medicines for both rare and broad CNS disorders, and we are becoming an enduring leader in neuroscience. Our first medicine, WAKIX® (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness or cataplexy in patients 6 years of age and older with narcolepsy. Its launch ranks among the most successful in the history of orphan drugs. Building on our success and profitability, we are continuing to advance our novel clinical-stage pipeline, led by BP-205, an investigational orexin-2 receptor agonist with best-in-class potential across a broad range of CNS disorders. With a strong balance sheet, we have the capacity and conviction to pursue strategic business development opportunities. Harmony is guided by an unwavering commitment to patients and driven to create long-term value for shareholders. For more information, visit: www.harmonybiosciences.com.
Current securities
Recent company filings
- SCHEDULE 13G - filed by AMERICAN CENTURY INVESTMENT MANAGEMENT INC regarding Harmony Biosciences Holdings, Inc.Nov 16, 2026
- 10-Q filingNov 4, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 4, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 30, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 13, 2026